Literature DB >> 22516623

Recovery from ischemic acute kidney injury by spironolactone administration.

Katy Sánchez-Pozos1, Jonatan Barrera-Chimal, Juan Garzón-Muvdi, Rosalba Pérez-Villalva, Roxana Rodríguez-Romo, Cristino Cruz, Gerardo Gamba, Norma A Bobadilla.   

Abstract

BACKGROUND: Prophylactic mineralocorticoid receptor (MR) antagonism with spironolactone (Sp) in rats completely prevents renal damage induced by ischemia. Because acute renal ischemia cannot typically be predicted, this study was designed to investigate whether Sp could prevent renal injury after an ischemic/reperfusion insult.
METHODS: Six groups of male Wistar rats were studied: rats that received a sham abdominal operation (S); rats that underwent 20 min of ischemia and reperfusion for 24 h (I/R) and four groups of rats treated with Sp (20 mg/kg) 0, 3, 6 or 9 h after ischemia.
RESULTS: As expected, I/R resulted in renal dysfunction characterized by a fall in renal blood flow and glomerular filtration rate and severe tubular injury which was confirmed by a significant increase in tubular damage biomarkers including kidney injury molecule-1, heat shock protein 72 and urinary protein excretion. The renal injury induced by I/R was in part due to Rho-kinase, endothelin and angiotensin II type 1 receptor upregulation. Interestingly, Sp administration at 0 and 3 h after ischemia completely reversed and prevented the damage induced by I/R. The protection induced by Sp given 6 h after ischemia was partial, but no protection was observed by administering Sp 9 h after ischemia.
CONCLUSION: Our results show that MR antagonism administered, either immediately or 3 h after I/R, effectively prevented ischemic acute renal injury, indicating that spironolactone is a promising agent for preventing acute kidney injury once an ischemic insult has occurred.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22516623     DOI: 10.1093/ndt/gfs014

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  15 in total

1.  Mineralocorticoid Receptor Antagonism in AKI: A New Hope?

Authors:  Luis A Juncos; Luis I Juncos
Journal:  J Am Soc Nephrol       Date:  2015-09-11       Impact factor: 10.121

2.  New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects.

Authors:  Ana Paula Davel; Iris Z Jaffe; Rita C Tostes; Frederic Jaisser; Eric J Belin de Chantemèle
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-29       Impact factor: 4.733

3.  Randomized Controlled Trial of Mineralocorticoid Receptor Blockade in Children with Chronic Kidney Allograft Nephropathy.

Authors:  Mara Medeiros; Luis Velásquez-Jones; Ana M Hernández; Guillermo Ramón-García; Saúl Valverde; Yolanda Fuentes; Arindal Vargas; Mauricio Patiño; Rosalba Pérez-Villalva; Juan Antonio Ortega-Trejo; Jonatan Barrera-Chimal; Norma A Bobadilla
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-23       Impact factor: 8.237

4.  Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia.

Authors:  Jonatan Barrera-Chimal; Sonia Prince; Fouad Fadel; Soumaya El Moghrabi; David G Warnock; Peter Kolkhof; Frédéric Jaisser
Journal:  J Am Soc Nephrol       Date:  2015-09-11       Impact factor: 10.121

Review 5.  Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?

Authors:  Hermann Haller; Anna Bertram; Klaus Stahl; Jan Menne
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

6.  Mild ischemic injury leads to long-term alterations in the kidney: amelioration by spironolactone administration.

Authors:  Jonatan Barrera-Chimal; Rosalba Pérez-Villalva; Juan Antonio Ortega; Andrea Sánchez; Roxana Rodríguez-Romo; Marta Durand; Frederic Jaisser; Norma A Bobadilla
Journal:  Int J Biol Sci       Date:  2015-06-06       Impact factor: 6.580

7.  Hsp72 is a novel biomarker to predict acute kidney injury in critically ill patients.

Authors:  Luis E Morales-Buenrostro; Omar I Salas-Nolasco; Jonatan Barrera-Chimal; Gustavo Casas-Aparicio; Sergio Irizar-Santana; Rosalba Pérez-Villalva; Norma A Bobadilla
Journal:  PLoS One       Date:  2014-10-14       Impact factor: 3.240

8.  The Effect of Spironolactone on the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Cardiac Catheterization: Study Design and Rationale.

Authors:  Alhasan Mujtaba; Mohammed A Taher; Mazin A Hazza; Hassan M Al-Rubaye; Asaad H Kata; Hamid AbdulWahab; AbdulAmeer AbdulBari; Hayder K AlRubay
Journal:  Cardiol Ther       Date:  2018-05-21

9.  Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: Insights from the LEVO-CTS trial.

Authors:  Oliver K Jawitz; Amanda S Stebbins; Vignesh Raman; Brooke Alhanti; Sean van Diepen; Matthias Heringlake; Stephen Fremes; Richard Whitlock; Steven R Meyer; Rajendra H Mehta; Mark Stafford-Smith; Shaun G Goodman; John H Alexander; Renato D Lopes
Journal:  Am Heart J       Date:  2020-10-28       Impact factor: 4.749

10.  Mineralocorticoid receptor blockade for renoprotection.

Authors:  Dae Ryong Cha
Journal:  Kidney Res Clin Pract       Date:  2018-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.